Akebia Therapeutics, Inc.AKBA

Akebia Therapeutics Inc. filed its 10-Q for the quarter ending 31 March 2026 on 7 May 2026, and the numbers tell a story that the glossy product pages do not. Product revenues came in at $53.5 million, a figure that sounds robust until you notice the operating cash burn of $21.2 million and the $14.8 million spent on research and development. The company markets two approved renal drugs-Auryxia and Vafseo-through a handful of dialysis clinics, wholesale distributors, and a single authorised generic partner, Mylan Therapeutics. Sales are not diversified; they are concentrated, like a doctor’s prescription pad with only two names on it.

Akebia describes itself as a ‘fully integrated renal biopharmaceutical company’ with ‘a late-stage product in global phase 3 clinical development and a commercially available medicine.’ Translation: it sells kidney drugs to dialysis patients while trying to keep its pipeline from going into renal failure. The company’s website, product pages, and social media guidelines focus on patient safety hotlines and adverse-event reporting, but the balance sheet is where the real therapy takes place. The cash balance is $162.6 million, yet operating activities used $21.2 million of cash in the quarter, and the company’s equity is a slender $27.4 million against $335.1 million in liabilities. That is not integration; it is triage.

The 10-Q shows product revenues of $51.99 million, an operating loss of $4.7 million, a net loss of $9.1 million, and diluted loss per share of $0.03. Research and development expense was $14.8 million, inventory rose by $2.5 million to $13.0 million, and capital expenditure was a modest $62,000. The weighted average diluted share count was 267.0 million shares. These are not the metrics of a company that has cracked the code on kidney disease; they are the metrics of a company that has cracked the code on filing filing trail. (source: AKBA SEC EDGAR 10-Q, 2026-05-07, https://www.sec.gov/Archives/edgar/data/1517022/000151702226000039/akba-20260331.htm)

The company’s commercial story rests on two approved drugs-Auryxia (an iron replacement therapy) and Vafseo (a phosphate binder)-with sales routed through dialysis organisations, wholesale distributors, specialty pharmacies, and Mylan under an authorised generic arrangement. The evidence on the corporate site confirms the product portfolio and the approved indications but does not disclose any new launches, label expansions, or geographic diversifications in the latest filings. The company’s research and development page stresses collaboration with healthcare professionals and researchers, yet the 10-Q shows no material change in clinical-stage assets or partnered programmes. The site also hosts crisis-management boilerplate-adverse event hotlines and social media guidelines-suggesting that the company’s real product is not just drugs, but also the filing trail of regulatory compliance. (source: Products - Akebia Therapeutics, https://akebia.com/medicine/; Research & Development - Akebia Therapeutics, https://akebia.com/research-and-development/; Social Media Guidelines - Akebia Therapeutics, https://akebia.com/social-media-guidelines/)

For readers who like to anchor stories in charts, the SEC filings do not supply price levels or trading volumes, and the company is listed on Nasdaq under the ticker AKBA, not on a regional exchange. The filings clock in at a steady stream of Forms 4, 8-K, and 144, but none of these documents contain share-price data or market-mechanism colour. If you want to see how the stock behaves, you will need to look elsewhere; the SEC rail here is strictly about disclosure, not valuation. (source: AKBA SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1517022)

What changed in the last month? On 1 July 2026, the company filed an annual report on Form 4, a routine disclosure of insider share transactions, and on 30 June 2026 it filed an 8-K disclosing a $15 million term loan draw-evidence that the company is tapping credit markets while burning cash from operations. A 144 filing on 29 June 2026 showed insider share sales, a detail that underscores the tension between financing needs and equity value. None of these events materially alter the company’s core metrics-revenue, cash burn, R&D spend, or equity-but they do illustrate the financing treadmill the business is running. (sources: AKBA 4 (2026-07-01), https://www.sec.gov/Archives/edgar/data/1517022/000176250726000004/xslF345X06/primarydocument.xml; AKBA 8-K (2026-06-30), https://www.sec.gov/Archives/edgar/data/1517022/000151702226000047/akba-20260630.htm; AKBA 144 (2026-06-29), https://www.sec.gov/Archives/edgar/data/1517022/000151702226000044/xsl144X01/primary_doc.xml)

What remains unproven? The company’s pipeline beyond the two commercially available drugs is not disclosed in the latest filings as materially advanced. The evidence on the corporate site suggests a commitment to collaboration and hypothesis-testing, but no phase 3 readouts, regulatory milestones, or partnering wins are evidenced in the SEC record. The company’s website imagery-staff portraits and lab shots-does not substitute for audited clinical data. Until the balance sheet shows sustained operating cash generation or a diversified revenue base, the polished story will continue to outpace the plain reality. (source: Home - Akebia Therapeutics, https://akebia.com/)